Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy MEI Pharma (MEIP) stocks in Canada

Learn how to easily invest in MEI Pharma stocks.

MEI Pharma is a biotechnology business based in the US. MEI Pharma stocks (MEIP.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.87 – a decrease of 9.64% over the previous week. MEI Pharma employs 76 staff and has a trailing 12-month revenue of around $35.1 million.

How to buy shares in MEI Pharma

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MEIP – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

MEI Pharma stock price (NASDAQ:MEIP)

Use our graph to track the performance of MEIP stocks over time.

MEI Pharma shares at a glance

Information last updated 2022-01-17.
Latest market close$2.25
52-week range$2.28 - $4.58
50-day moving average $2.70
200-day moving average $2.90
Wall St. target price$10.89
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.69

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy MEI Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

MEI Pharma price performance over time

Historical closes compared with the close of $2.25 from 2022-01-20

1 week (2022-01-13) -7.02%
1 month (2021-12-21) -10.36%
3 months (2021-10-21) -17.88%
6 months (2021-07-21) -17.58%
1 year (2021-01-21) -21.88%
2 years (2020-01-21) -7.02%
3 years (2019-01-18) 2.73
5 years (2017-01-20) 46.10%

Is MEI Pharma under- or over-valued?

Valuing MEI Pharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of MEI Pharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

MEI Pharma's PEG ratio

MEI Pharma's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 20.6. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into MEI Pharma's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

MEI Pharma financials

Revenue TTM $35.1 million
Gross profit TTM $-41,127,000
Return on assets TTM -21.96%
Return on equity TTM -105.76%
Profit margin -172.03%
Book value $0.28
Market capitalisation $330.8 million

TTM: trailing 12 months

MEI Pharma share dividends

We're not expecting MEI Pharma to pay a dividend over the next 12 months.

Have MEI Pharma's shares ever split?

MEI Pharma's shares were split on a 1:6 basis on 18 December 2012. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your MEI Pharma shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for MEI Pharma shares which in turn could have impacted MEI Pharma's share price.

MEI Pharma share price volatility

Over the last 12 months, MEI Pharma's shares have ranged in value from as little as $2.28 up to $4.58. A popular way to gauge a stock's volatility is its "beta".

MEIP.US volatility(beta: 1.33)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MEI Pharma's is 1.3335. This would suggest that MEI Pharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

MEI Pharma overview

MEI Pharma, Inc. , a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd. ; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc.

Stocks similar to MEI Pharma

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site